Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.
Details
Serval ID
serval:BIB_29592
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.
Journal
Journal of Immunology
ISSN
0022-1767 (Print)
ISSN-L
0022-1767
Publication state
Published
Issued date
2003
Volume
171
Number
9
Pages
4898-4904
Language
english
Notes
Publication types: Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Abstract
We have analyzed the T cell responses of HLA-A1 metastatic melanoma patients with detectable disease, following vaccination with a recombinant ALVAC virus, which bears short MAGE-1 and MAGE-3 sequences coding for antigenic peptides presented by HLA-A1. To evaluate the anti-MAGE CTL responses, we resorted to antigenic stimulation of blood lymphocytes under limiting dilution conditions, followed by tetramer analysis and cloning of the tetramer-positive cells. The clones were tested for their specific lytic ability and their TCR sequences were obtained. Four patients who showed tumor regression were analyzed, and an anti-MAGE-3.A1 CTL response was observed in three of these patients. Postvaccination frequencies of anti-MAGE-3.A1 CTL were 3 x 10(-6), 3 x 10(-3), and 3 x 10(-7) of the blood CD8 T cells, respectively. These three responses were monoclonal. No anti-MAGE-1.A1 CTL response was observed. These results indicate that, like peptide immunization, ALVAC immunization produces monoclonal responses. They also suggest that low-level antivaccine CTL responses can initiate a tumor regression process. Taken together, our analysis of anti-MAGE-3.A1 T cell responses following peptide or ALVAC vaccination shows a degree of correlation between CTL response and tumor regression, but firm conclusions will require larger numbers.
Keywords
Antigens, Neoplasm/administration & dosage, Antigens, Neoplasm/genetics, Canarypox virus/genetics, Canarypox virus/immunology, Cancer Vaccines/administration & dosage, Cancer Vaccines/genetics, Clone Cells, Female, Humans, Injections, Intradermal, Injections, Subcutaneous, Lymphatic Metastasis/immunology, Lymphatic Metastasis/prevention & control, Melanoma/immunology, Melanoma/prevention & control, Neoplasm Proteins/administration & dosage, Neoplasm Proteins/genetics, Polymerase Chain Reaction, Receptors, Antigen, T-Cell/biosynthesis, Receptors, Antigen, T-Cell/blood, T-Lymphocytes, Cytotoxic/immunology, T-Lymphocytes, Cytotoxic/metabolism, Vaccines, Subunit/administration & dosage, Vaccines, Subunit/genetics, Vaccines, Synthetic/administration & dosage, Vaccines, Synthetic/genetics, Viral Vaccines/administration & dosage, Viral Vaccines/genetics
OAI-PMH
Pubmed
Web of science
Open Access
Yes
Create date
19/11/2007 13:27
Last modification date
20/08/2019 14:09